The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...

HUTCHMED has initiated a global phase 1/2a clinical trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in patients with unresectable, advanced or metastatic solid tumours in China and ...

Bioxytran has announced encouraging results from a randomized, double‑blind, placebo‑controlled phase 1b/2a study of its oral ...

The approvals are supported by the REAL8 study, which showed Sogroya was non‑inferior to daily growth hormone therapy across all three indications. Adverse reactions occurring in at least 10% of ...

A new UK‑developed artificial intelligence system is being positioned as a potential breakthrough in the early identification of Alzheimer’s disease, aiming to reduce the number of people who remain ...

Quell Therapeutics has begun its chill phase 1/2 clinical trial evaluating QEL‑005, an autologous CAR‑Treg therapy designed for people with rheumatoid arthritis and systemic sclerosis. The move ...

AlzeCure Pharma has announced that the European Medicines Agency has granted orphan drug status to ACD440, its clinical‑stage ...

Lario Therapeutics has secured $2.4 million in new grant funding from The Michael J Fox Foundation for Parkinson’s Research ...

ViiV Healthcare has announced new 96‑week findings from a sub‑group analysis of the PASO DOBLE study, showing that adults ...

The Medicines and Healthcare products Regulatory Agency has approved imlunestrant tosylate, branded as Inluriyo, for adults ...

The Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for brensocatib, branded as Brinsupri, marking the first time a medicine specifically designed to treat ...

Gilead has released new phase 3 data from its ARTISTRY‑1 and ARTISTRY‑2 trials assessing treatment responses in adults with HIV who are virologically suppressed, including those switching from complex ...